KueiFu (Tom) Lin, D.V.M., Medical University of South Carolina (MUSC): Based on the report of an investigation conducted by MUSC and additional analysis conducted by ORI in its oversight review, the U.S. Public Health Service (PHS) found on June 12, 2001, that Dr. Lin, a former graduate student, Department of Biochemistry and Molecular Biology at MUSC, engaged in scientific misconduct in research supported by the National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grants R01 HL29397, ``Regulation and Function of Renal Kallikrein,'' and R01 HL56686, ``Gene Therapy in Experimental Hypertension and Renal Diseases,'' by falsifying data published in publications in Hypertension 26:847853, 1995, Hypertension Research 20:269277, 1997, and Human Gene Therapy 9:1429 1438, 1998.

Subsequent to the exec ]]> http://thefederalregister.com/d.p/2003-12-09-03-30536 Tue, Dec 9 2003 11:00:00 GMT http://thefederalregister.com/d.p/2003-12-09-03-30535

Jianhua (James) Xu, M.S., University of Alberta: Based on the University of Alberta (UA) Report, the respondent's admissions, and additional analysis conducted by ORI in its oversight review, the U.S. Public Health Service (PHS) found that Jianhua (James) Xu, M.S., former technician at UA, engaged in scientific misconduct in research funded by National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH), grant R01 HL6175101.

Mr. Xu performed experiments on the enzyme lipid phosphate phosphatase1 (LPP1) from a family of enzymes that affect signal transduction by glycerolipid and sphingolipid phosphate esters as second messengers. A typical experiment involved the investigation of the effects on various glycerolipids, sphingolipids, and other related effector compounds on the activity of LPP1 either in tiss ]]> http://thefederalregister.com/d.p/2003-12-09-03-30535 Tue, Dec 9 2003 11:00:00 GMT